Subtotal $0.00
Shop Now
Zepbound and alcohol is one of the most common questions people ask after starting a GLP-1 drug. The short answer: the U.S. label for Zepbound (tirzepatide) does not list alcohol as a drug interaction or a reason not to use the medicine, and the same is true for Mounjaro, Ozempic and Wegovy. Eli Lilly says it has not studied tirzepatide together with alcohol. Several label warnings still overlap with what alcohol does in the body: low blood sugar, pancreatitis, and dehydration from vomiting or diarrhea. Separately, a growing body of research suggests GLP-1 drugs may reduce drinking, but no GLP-1 drug is FDA-approved for that use.
Peptide Labs does not sell tirzepatide, semaglutide or any prescription drug. This article is general information, not medical advice. How alcohol fits with your medicine is a question for your prescriber or pharmacist. For background on the drug class, see what GLP-1 is.
Key Takeaways
- No U.S. label for Zepbound, Mounjaro, Ozempic or Wegovy lists alcohol as an interaction or contraindication.
- Lilly says it has not studied tirzepatide with alcohol and excluded people with a history of alcohol abuse from its trials.
- Alcohol makes blood sugar harder to keep steady, and the labels warn about low blood sugar, especially with insulin or sulfonylureas.
- Heavy alcohol use is one of the two most common causes of pancreatitis, a serious warning on each of these labels.
- Randomized trials of semaglutide in people with alcohol use disorder show reductions in some drinking measures; this is research, not an approved use.
- Alcohol adds calories with few nutrients: about 150 in a 12-ounce regular beer.
Zepbound and alcohol: what the label and Lilly say
The current Zepbound prescribing information, revised in August 2026, mentions alcohol only once: benzyl alcohol, a preservative in the KwikPen. Lilly’s medical information team notes that benzyl alcohol does not contain or turn into ethanol, the alcohol in drinks.
In a statement updated in December 2025, Lilly says it has not evaluated tirzepatide with alcohol use or for alcohol use disorder, that people with a history of alcohol abuse were excluded from its clinical trials, and that tirzepatide is not indicated for alcohol use disorder. The company gives no recommendation either way and leaves the decision to the prescriber, based on each person’s history.
Ozempic and alcohol, Wegovy and alcohol, Mounjaro and alcohol
The picture is the same across the class. We searched the full U.S. labels for Mounjaro (revised August 2026), Ozempic (May 2026), Wegovy (June 2026) and the semaglutide tablets (January 2026). None gives an alcohol warning. So the answer to GLP-1 and alcohol questions comes from the warnings these drugs share, set against what alcohol is known to do.
| Label warning (all four drugs) | What the label says | Where alcohol overlaps |
|---|---|---|
| Low blood sugar | Risk rises with insulin or sulfonylureas; Zepbound and Wegovy labels also note cases in adults without diabetes | Alcohol makes blood sugar harder to keep steady and can mask early symptoms (NIDDK) |
| Acute pancreatitis | Fatal and non-fatal cases reported; stop the drug if suspected | Heavy alcohol use is a leading cause of pancreatitis (NIDDK) |
| Kidney injury from fluid loss | Most reports followed nausea, vomiting or diarrhea with dehydration | Alcohol increases urination and fluid loss (NIAAA) |
| Digestive side effects | Nausea, vomiting and diarrhea are among the most common | Alcohol irritates the stomach lining and can cause nausea (NIAAA) |
| Slower stomach emptying | Zepbound delays gastric emptying | Small studies suggest alcohol may be absorbed more slowly |
Low blood sugar
The Zepbound label says the drug lowers blood glucose and can cause hypoglycemia. In a trial of adults with type 2 diabetes, low blood sugar was reported in 4.2% on Zepbound and 1.3% on placebo, rising to 10.3% in people also taking a sulfonylurea, compared with 2.1% in those who were not. The label adds that the risk is higher with insulin, and that low blood sugar has also been seen in adults without diabetes.
Alcohol works on the same problem from another direction. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) says alcohol makes it harder for the body to keep blood glucose steady, especially after a long gap without food, and can hide the first symptoms of a low, so it is safer to eat when drinking. Anyone on insulin or a sulfonylurea alongside Mounjaro, Ozempic or Zepbound should ask their care team how to handle this.
Pancreatitis
Each of these labels warns that acute pancreatitis, including fatal hemorrhagic or necrotizing forms, has been seen with these drugs. The warning sign the labels describe is persistent, severe stomach pain, sometimes spreading to the back, with or without vomiting; the drug should be stopped and medical care sought if pancreatitis is suspected. According to the NIDDK, the most common causes of both acute and chronic pancreatitis are gallstones and heavy alcohol use. Gallbladder disease is also a GLP-1 label warning, so a history of pancreatitis, gallstones or heavy drinking is worth raising with a prescriber.
Dehydration, vomiting and kidney injury
The labels report acute kidney injury, sometimes needing dialysis, mostly in people who became dehydrated after nausea, vomiting or diarrhea, and they advise kidney checks in that situation. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) explains that alcohol suppresses vasopressin, a hormone that tells the kidneys to hold on to water, so drinking increases urination and fluid loss and can irritate the stomach. Digestive side effects are most common in the weeks after starting or stepping up a GLP-1 drug, as our guides to tirzepatide side effects and semaglutide side effects explain.
Why alcohol may feel different on a GLP-1 drug
GLP-1 drugs slow the rate at which the stomach empties; the Zepbound label states this directly. In a 2025 pilot study from Virginia Tech, 20 adults with obesity, half taking a GLP-1 drug and half not, drank a set amount of alcohol. Breath alcohol and the felt effects rose more slowly in the GLP-1 group, not explained by nausea. A 2023 remote study by the same group of 153 drinkers with obesity found that people on semaglutide or tirzepatide reported drinking less, and feeling less stimulation and sedation from alcohol, than before they started. Both studies are small, and the second relied on self-reports.
Do GLP-1 drugs reduce drinking? What the research shows
Animal studies first linked GLP-1 signaling to lower alcohol intake. Human trials mostly involve semaglutide or exenatide in people with alcohol use disorder:
- Exenatide, 2022 (JCI Insight): 127 adults with alcohol use disorder received weekly exenatide or placebo for 26 weeks alongside counseling. Heavy drinking days did not fall significantly overall; an exploratory analysis found reductions in participants with obesity.
- Semaglutide, 2025 (JAMA Psychiatry): 48 adults with alcohol use disorder who were not seeking help, 9 weeks. Semaglutide reduced how much people drank in a laboratory session, drinks per drinking day and craving, but not the number of drinking days. Funded by the NIH.
- Semaglutide, 2026 (The Lancet): 108 adults with moderate to severe alcohol use disorder and obesity, 26 weeks with counseling. Heavy drinking days fell by 41.1 percentage points with semaglutide and 26.4 with placebo. Funders included the Novo Nordisk Foundation.
- Oral semaglutide, 2026 (American Journal of Psychiatry): 50 adults seeking help, 8 weeks. Craving in the lab, the main measure, did not change significantly; heavy drinking days and drinks per drinking day fell.
Large observational studies point the same way but cannot prove cause and effect. A U.S. health-records study of 83,825 people with obesity linked semaglutide to a 50% to 56% lower risk of a new or recurring alcohol use disorder diagnosis over a year. A Swedish study of 227,866 people with alcohol use disorder found fewer alcohol-related hospital stays during periods on semaglutide or liraglutide, and a 2026 U.S. study of 40,703 adults linked starting semaglutide or tirzepatide to fewer alcohol-related emergency visits and hospital stays.
Evidence for tirzepatide specifically is thinner. Lilly says it has no plans to study tirzepatide for alcohol use disorder, but a University of Southern California phase 2 trial with NIAAA support and an NIAAA phase 1 study are recruiting. Lilly completed a phase 2 trial of a related experimental drug, mazdutide, in 308 people with alcohol use disorder in March 2026; no results had been posted by late September 2026. No GLP-1 drug is FDA-approved for alcohol use disorder.
Alcohol calories and weight goals
A U.S. standard drink holds about 14 grams of pure alcohol, the amount in a 12-ounce regular beer, a 5-ounce glass of wine or a 1.5-ounce shot of spirits. The Dietary Guidelines for Americans list about 150 calories for that beer, 120 for the wine, 100 for the spirits and 190 for a rum and cola, with few nutrients. The 2025-2030 Dietary Guidelines advise drinking less for better health and say people taking medicines or with conditions that can interact with alcohol should avoid it completely. Our GLP-1 diet guide covers protein, fluids and eating patterns on these drugs.
Questions to raise with your prescriber
- Do you take insulin or a sulfonylurea, and what should you do about low blood sugar if you drink?
- Have you had pancreatitis, gallstones or a period of heavy drinking?
- Are you having nausea, vomiting or diarrhea that could leave you dehydrated?
- Do you have a procedure with anesthesia coming up? The labels ask you to tell your care team you take a GLP-1 drug.
- Are you worried about your drinking? Help is available whether or not you take a GLP-1 drug.
For a drug-by-drug rundown, see Zepbound side effects and Mounjaro vs Zepbound. Products sold online as “research” tirzepatide or semaglutide are not FDA-approved; our guide to compounded semaglutide and tirzepatide explains the difference.
Frequently Asked Questions
Can you drink alcohol on Zepbound?
The Zepbound label does not forbid alcohol or list it as an interaction, and Lilly has not studied the combination. Its warnings about low blood sugar, pancreatitis and dehydration overlap with alcohol’s effects, so ask your prescriber what is reasonable for you.
Does alcohol interact with Ozempic?
The Ozempic label, revised in May 2026, lists no alcohol interaction. Alcohol can still lower blood sugar, which matters most for people also taking insulin or a sulfonylurea.
Is Wegovy and alcohol a dangerous combination?
There is no label warning about it, but heavy drinking is a major cause of pancreatitis, and pancreatitis is a serious warning on the Wegovy label. Drinking can also add to dehydration when digestive side effects occur.
Can GLP-1 drugs reduce alcohol cravings?
Randomized trials of semaglutide in adults with alcohol use disorder have found reductions in some drinking measures and in craving, and large observational studies agree. These drugs are not FDA-approved for alcohol use disorder, and larger trials are ongoing.
Does alcohol affect weight loss on Mounjaro or Zepbound?
No trial has measured this directly. Alcohol does add calories with few nutrients, about 150 in a 12-ounce regular beer according to the Dietary Guidelines. Mounjaro is approved for type 2 diabetes, not weight loss.
Peptide Labs does not sell these drugs. This article is general information, not medical advice. Read the Medication Guide that comes with a prescription, and ask a pharmacist or prescriber how this information applies to you. If you are concerned about your drinking, your doctor can help, whether or not you take a GLP-1 drug.
Last reviewed September 2026.
Related guides: GLP-1 Diet: What Experts Recommend While on GLP-1 Medicines, Semaglutide Side Effects: What the Ozempic, Wegovy and Rybelsus Labels Say, Tirzepatide Side Effects: What the Mounjaro and Zepbound Labels Say.